Subclinical thyroid disease after radiation therapy detected by radionuclide scanning.
OBJECTIVE
The actuarial risk for developing benign or malignant thyroid disease following radiation therapy (RT) is controversial, but may be as high as 50% at 20 years. An effective screening modality should be specific but not overly sensitive, a limitation of ultrasound. We questioned whether Technetium-99 m pertechnetate ((99m)Tc TcO(4)(-)) scanning could detect clinically significant disease in ostensibly disease-free cancer survivors.


METHODS
Eligibility criteria included an interval of at least 5 years after RT to the cervical region, a thyroid gland that was normal to palpation, euthyroid status determined by clinical examination, free T4 and TSH. The 34 patients scanned included 16 children (<18 years old) and 18 adults at the time of RT, 16 females and 18 males. The mean age at RT was 20 years (range, 2.1-50.3 years), and the mean age at (99m)Tc TcO(4)-scanning was 33 years (range, 13.6-58 years), providing a mean interval of 13 years (range, 5.3-26.6 years). The mean RT dose to the thyroid was 36.4 Gy (range, 19.5-52.5). Thyroid scanning was performed with a 5 mCi dose of (99m)Tc TcO(4)(-) obtaining flow, immediate and delayed static, and pinhole collimator images.


RESULTS
Seven patients (21.6%) had abnormal scans, and the percentage was higher among children (25%) and females (25%) compared to adults (16.7%) and males (16.7%), respectively. Two of 34 patients (5.9%) were discovered to have a thyroid cancer; histopathologies were papillary and follicular carcinoma.


CONCLUSIONS
In this population of clinically normal cancer survivors who had been irradiated to the cervical region, subclinical thyroid disease, of potential clinical significance, was detected by (99m)Tc TcO(4)(-) in about 20%. Children may be more commonly affected. Although the cost effectiveness of screening will require a larger sample number, we propose a surveillance schema for this patient population.
Department of Radiation Oncology, University of Rochester Medical Center, Rochester, NY 14642, USA.
A
A
Sandhu
L S
LS
Constine
R E
RE
O'Mara
A
A
Hinkle
A G
AG
Muhs
P D
PD
Woolf
D000293:Adolescent; D000328:Adult; D002277:Carcinoma / Q000000981:diagnostic imaging / Q000209:etiology; D002528:Cerebellar Neoplasms / Q000532:radiotherapy; D002648:Child; D002675:Child, Preschool; D005260:Female; D006689:Hodgkin Disease / Q000532:radiotherapy; D006801:Humans; D008297:Male; D008527:Medulloblastoma / Q000532:radiotherapy; D009381:Neoplasms, Radiation-Induced / Q000000981:diagnostic imaging* / Q000209:etiology; D016609:Neoplasms, Second Primary / Q000000981:diagnostic imaging* / Q000209:etiology; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals; D013670:Sodium Pertechnetate Tc 99m; D013961:Thyroid Gland / Q000000981:diagnostic imaging* / Q000528:radiation effects; D013964:Thyroid Neoplasms / Q000000981:diagnostic imaging* / Q000209:etiology
D019275:Radiopharmaceuticals; D013670:Sodium Pertechnetate Tc 99m